KLRC1 and colorectal carcinoma: In particular, the best therapeutic approach could be achieved by combining cell engagers with NKG2A/KIRs blockade in MSS CRC or with both PD-1/PD-L1 and NKG2A/KIRs blockade in MSI CRC.